AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1 x matched to Moxifloxacin capsule
Study NCT00887770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 x matched to Moxifloxacin capsule
Study NCT04496323 — intervention group
Intervention type: OTHER
Intervention: EE Golf
Description: Exercise in Golf and Playing 9 holes
Study NCT04197076 — intervention group
Intervention type: DRUG
Intervention: anti-PD-1 or anti-PD-L1
Description: immunotherapy anti-PD-1 or anti-PD-L1
Study NCT04197076 — intervention group
Intervention type: DRUG
Intervention: EGFR-TKI, ALK inhibitor, ROS1 inhibitor
Description: targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor
Study NCT04197076 — intervention group
Intervention type: DRUG
Intervention: investigator decided
Description: chemotherapy
Study NCT00092053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study NCT00092053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: 50 mg tablets
Study NCT01495351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888/Bortezomib
Description: ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
Study NCT03990740 — intervention group
Intervention type: PROCEDURE
Intervention: Corneal sampling
Description: Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
Study NCT04510480 — intervention group
Intervention type: OTHER
Intervention: Observational study without specific intervention
Description: Observational study with standard cardiac arrest approach
Study NCT02465918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor cortex stimulation (Change of Stimulation Timing)
Study NCT02465918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: motor cortex stimulation (Change of Stimulation Timing)
Study NCT02406248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Description: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Study NCT01777334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Inhalation Powder
Study NCT01777334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: Inhalation Powder
Study NCT02565433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
Study NCT01436747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 2 micrograms daily, peroral, 24 weeks
Study NCT01436747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 micrograms daily, peroral, 24 weeks
Study NCT03322553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GERD-X
Description: Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
Study NCT03322553 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GERD-X
Description: Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
Study NCT04685447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded Hemodialysis for Covid19 maintenance hemodialysis patients
Description: After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
Study NCT04685447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients
Description: After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
Study NCT02402322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled support
Description: Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
Study NCT02402322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-scheduled support
Description: Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
Study NCT02833298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated reminders
Description: At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
Study NCT02833298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
Study NCT04746885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: DHA
Description: Oral supplement
Study NCT03763045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily
Study NCT03763045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily
Study NCT03763045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet.
Study NCT02567305 — intervention group
Intervention type: OTHER
Intervention: Markers of NET formation
Description: i.e. Plasma DNA, Histone, MPO, DNase
Study NCT02053883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethrin (BA-210)
Description: High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
Study NCT02053883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
Study NCT03219762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabpaclitaxel
Description: Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
Study NCT01304498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: 9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
Study NCT01304498 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL
Description: Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
Study NCT01340001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the nucleus basalis of Meynert
Description: Differents parameters will be assessed.
Study NCT01340001 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electrical stimulation of the nucleus basalis of Meynert
Description: Differents parameters will be assessed.
Study NCT03804606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to MTM Pharmacist
Description: Patients will be referred for an encounter with a medication therapy management pharmacist.
Study NCT03804606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to MTM Pharmacist
Description: Patients will be referred for an encounter with a medication therapy management pharmacist.
Study NCT01854307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum and SVV/PPV
Study NCT02627378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Membrane Oxygenation
Description: Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
Study NCT02627378 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Extracorporeal Membrane Oxygenation
Description: Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
Study NCT01497106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
Study NCT01497106 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (normal living)
Description: Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
Study NCT04065126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Ten sessions (two hours each) with physical activity and psycho-educational components.
Study NCT04065126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief psycho-education
Description: Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
Study NCT04338789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
Study NCT01080300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended Release
Description: Gabapentin ER 1800mg daily
Study NCT01080300 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Sugar pill
Study NCT03035110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioural Therapy (DBT) based skills groups
Description: Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
Study NCT01018108 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single Photon Emission Computed Tomography
Description: Undergo single photon emission computed tomographt imaging
Study NCT01018108 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acupuncture Therapy
Description: Undergo acupuncture
Study NCT01018108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary study
Study NCT01018108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative Study
Study NCT01982409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine
Study NCT03131947 — intervention group
Intervention type: OTHER
Intervention: HIV positive patients
Description: As above
Study NCT04852913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen's Technique
Description: The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week
Study NCT04852913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convention Physical Therapy
Description: Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week
Study NCT02446613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pollen allergen extract
Description: Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
Study NCT01808183 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy Pads
Description: NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
Study NCT03463499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid and Chondroitin Sulfate
Description: Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
Study NCT02601209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given PO
Study NCT02601209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT02601209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT04368845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The treatment arm will be given up to 1-hour breathing exercises, aerobic and resistive training exercises administered by a physiotherapist via a telerehabilitation device every 10 days for a six-month period.
Study NCT01857726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Transarterial chemoembolization (TACE) with adriamycin
Study NCT03315494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703 capsule
Description: SKI-O-703 200 mg capsule with no inactive excipients.
Study NCT03315494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo 180 mg capsule filled with microcrystalline cellulose.
Study NCT01857726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Transarterial chemoembolization (TACE) with adriamycin
Study NCT01857726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: transarterial chemoinfusion with cisplatin 50-100 mg
Study NCT02281162 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw
Study NCT01421745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural Competence Education module
Description: A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
Study NCT04242407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMTS
Description: DMTS applied before surgery and worn for 96 hours
Study NCT04242407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Study NCT00134758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: During 2 years :~* between 40 and 50 kg : 500 mg/day~* between 51 and 75 kg : 750 mg/day~* between 76 and 100 kg : 1000 mg/day
Study NCT00134758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day
Study NCT04891926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICIQ FLUTS Questionaires
Description: Questionnaire observing the impact on voiding disfunctions
Study NCT04891926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Frequency Volume Chart
Description: Frequency Volume Chart measures the voided volumes and fluid intake during 3 days in order to observe patients bladder capacity, total and nighttime voided volume and voiding frequency
Study NCT04891926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal Function Profile
Description: The RFP is a 24-hour urine analysis in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. This RFP was collected on a separated day to the FVC. Daytime samples were taken between 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The night-time samples were taken between 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8), and the volume of each interim void, was noted to calculate the 24h, daytime and night-time urine volume and diuresis rate. On each of this 8 samples, creatinine, osmolality, sodium and urea concentration were analysed. Subsequently, the renal clearance of creatinine, solutes, sodium and potassium (Usubst x Uflow / Psubst) and FWC (urine flow - solute clearance) were calculated.
Study NCT04891926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Analysis
Description: Blood analysis in order to observ postmenopausal state, osmolalitity and sodium.
Study NCT01343784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urinary voiding assessment after midurethral sling
Description: Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
Study NCT01343784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinary voiding assessment after midurethral sling
Description: Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
Study NCT04350164 — intervention group
Intervention type: DRUG
Intervention: Romiplostim
Description: romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
Study NCT02496741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and chloroquine combination
Description: Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
Study NCT03992898 — intervention group
Intervention type: OTHER
Intervention: No special intervention was suitable for this observational study
Description: Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
Study NCT00983138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant asparaginase
Description: 10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
Study NCT00651144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Rosuvastatin
Description: oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
Study NCT00651144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
Study NCT00651144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; two ezetimibe placebo once daily for 14 days